• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Genetic Variants Specific to Critical COVID-19: Insights From Genome-Wide Association Studies and Structural Analysis

tetano

Editor, Senior Moderator
J Med Virol


. 2025 Nov;97(11):e70719.
doi: 10.1002/jmv.70719. Genetic Variants Specific to Critical COVID-19: Insights From Genome-Wide Association Studies and Structural Analysis

Hongwei Chen[SUP] 1 2 [/SUP], Zan Li[SUP] 1 2 [/SUP], Xue Han[SUP] 3 [/SUP], Shumiao Zhang[SUP] 1 2 [/SUP], Haoyang Zhang[SUP] 4 [/SUP], Yongkun Chen[SUP] 5 [/SUP], Yuelong Shu[SUP] 1 2 3 [/SUP]



Affiliations
Abstract

Genome-wide association studies (GWAS) have identified numerous genetic loci associated with COVID-19 susceptibility and severity. However, it remains unclear which variants specifically contribute to the progression from hospitalization to critical illness. To address this, we identified 394 symptom-differentiating SNPs (sdSNPs) by directly comparing GWAS summary statistics between critical and hospitalized COVID-19 cases. Among these, 13 were missense variants that may trigger phenotype conversion. To investigate their functional consequences, we performed structural modeling to evaluate the impact of these variants on protein stability. Eight proteins were predicted to be affected, including FUT2, ICAM5, IFNA10, PLSCR1, IZUMO1, ICAM1, RASIP1, and MICB, suggesting potential disruptions in immune signaling and host response pathways. Furthermore, Mendelian randomization analyses provided direct causal evidence: SMR analysis based on lung eQTL data demonstrated that higher FUT2 expression was significantly associated with increased risk of critical COVID-19 (β = 0.227, p = 2.69 × 10[SUP]-3[/SUP]), compared to a weaker effect in hospitalized COVID-19 (β = 0.096, p = 3.97 × 10[SUP]-2[/SUP]). In contrast, MR analysis using cis-pQTLs revealed that higher plasma levels of soluble ICAM5 (sICAM5) exerted protective effects, with stronger estimates in critical COVID-19 (β = -0.186, p = 5.54 × 10[SUP]-7[/SUP]) than in hospitalized COVID-19 (β = -0.095, p = 1.69 × 10[SUP]-4[/SUP]). These findings identify a distinct set of severity-specific genetic variants and offer mechanistic insights into how missense mutations may influence disease progression through structural and regulatory pathways.

Keywords: COVID‐19 severity; Mendelian randomization; missense variants; protein structure prediction; symptom‐differentiating SNPs.

 
Back
Top